1. Trends in the use and role of biomarkers in phase I oncology trials;Goulart;Clin Cancer Res.,2007
2. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2;Spratlin;J Clin Oncol.,2010
3. US Food and Drug Administration Approved Drugs: Ramucirumab (Cyramza). Available from URL: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm426735.htm [accessed April 8, 2015].
4. US Food and Drug Administration Approved Drugs: Ramucirumab. Available from URL: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm394260.htm [accessed April 8, 2015].
5. US Food and Drug Administration: Drug Development & Approval Process. Available from URL: http://www.fda.gov/drugs/developmentapprovalprocess/drugdevelopmenttoolsqualificationprogram/ucm284076.htm [accessed July 10, 2014].